<DOC>
	<DOC>NCT01174992</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of EVICEL for use as an adjunct to dura sutures in elective cranial surgery to provide intraoperative watertight closure.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair</brief_title>
	<detailed_description>This is a randomized, multi-center controlled study evaluating the effectiveness of EVICEL* as an adjunct to sutured dural closure compared to control to obtain an intraoperative watertight dural closure.</detailed_description>
	<criteria>Patient undergoing elective craniotomy/craniectomy Age greater than or equal to 18 years Patients who are able and willing to comply with the procedures required by the protocol. Signed and dated written informed consent from the subject or from his/her legal representative prior to any studyrelated procedures. Chemotherapy or radiation therapy within 7 days following surgery. Conditions compromising the immune system. Known hypersensitivity to the components (human fibrinogen, arginine hydrochloride, glycine, sodium chloride, sodium citrate, calcium chloride, human thrombin, human albumin, mannitol and sodium acetate) of the investigational product. Female subjects of childbearing potential with a positive pregnancy test prior to surgery. Female subjects who are breastfeeding or intend to become pregnant during the clinical study period. Participation in another clinical trial with exposure to another investigational drug or device within 30 days prior to enrollment. Major intraoperative findings or complications identified by the surgeon that may preclude conduct of the planned surgical procedure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Fibrin sealant</keyword>
	<keyword>CSF leak</keyword>
</DOC>